OKLAHOMA CITY, OKLAHOMA — The Hough Ear Institute (HEI) will receive $300,000 in funding to support its research into treatments for hearing loss and tinnitus.
According to a report on OKCFox, HEI ranked ninth out of 63 proposals in a grant by the Oklahoma Center for the Advancement of Science and Technology (OCAST).
OCAST awarded the funds to HEI to advance a hearing-loss pill which could preserve and maybe even restore natural hearing for people.
The pill, known as NHPN-1010, is awaiting Phase 2 testing by Oblato Inc., which holds rights to the drug.
Oblato is expected to initiate a phase 2 clinical trial to evaluate the potential of the drug to prevent and treat hearing loss. Follow-up studies may test efficacy for treating tinnitus and improving ability to understand speech in the presence of background noise.
At this time, no drug treatment or cure exists for noise induced hearing loss (NIHL) or tinnitus.
About the Hough Ear Institute
The Hough Ear Institute (HEI) is a nonprofit 501(c)(3) organization committed to restoring hearing worldwide through research, teaching and humanitarian efforts.
